Please select the eligibility criteria that correspond to the clinical trial below.
Title: Treatment of Hidradenitis Suppirativa With Etanercept Injection
Brief Summary: Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.


Options:
A: Inclusion Criteria:

For inclusion, the subject must:

* Be at least 18 years old
* Be otherwise healthy
* Have a diagnosis of HS
* Patients with Hurley stage II, with one ore more widely separated recurrent abscesses, with a tract and scarring, bilateral and symmetrical, will be eligible for inclusion in the study.
* Agree to abide by the Investigator's guidelines regarding photosensitizing drugs
* Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
* Agree to follow and undergo all study-related procedures.

Exclusion Criteria:

* Patients with Hidradenitis Hurley state I and III will be excluded from participation in the study.
* The control for this study will be the patient's opposite side of the body, i.e., for patients treated on the left axilla, the right axilla will serve as the corresponding control.
* Concomitant use of systemic or topical treatments for HS. Patients must discontinue all forms of oral therapy as systemic and topical antibiotics and retinoids for 2 weeks prior to the start of any treatment.
* Exacerbation of the patient's original condition expressed clinically by a shift from Hurley Stage II to Stage III.
B: Inclusion Criteria:

* Adults with stable, moderate to severe hidradenitis suppurativa
* Negative Chest X-ray and PPD test at Screening. If participant has had a past ulcerative reaction to PPD placement and/or chest X-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy.
* Ability to administer subcutaneous injections
* General good health otherwise

Exclusion Criteria:

* Prior anti-TNF therapy
* Unstable antibiotic therapy for HS
* Required medication washouts for other HS treatments
* Prior exposure to Tysabri® (natalizumab);
* Recent infection requiring treatment
* Significant medical events or conditions that may put patients at risk for participation
* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;
* History of cancer, except successfully treated skin cancer
* Recent history of drug or alcohol abuse
C: Inclusion Criteria:

* Person must have moderate to severe Hidradenitis suppurativa
* Multiple ER or doctors visits related to HS
* Intralesional kenalog injection \>5/year, but none within 3 months of entry
* HS \>1 year duration
* Failed systemic retinoids, but not within 3 months of entry
* Failed at least one prior course of antibiotic therapy, which must not have been administered within 3 months of entry to the study (excluding the recommended antibiotic regimen given immediately before randomization for evidence of active infection
* History of surgery (reconstructive), but not within 3 months of entry

Exclusion Criteria:

* Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion
* Known allergy against infliximab
* Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent).
* Have had any previous treatment with monoclonal antibodies or antibody fragments.
* Have a known history of serious infections (eg, hepatitis, pneumonia or pyelonephritis) in the previous 3 months.
* Have or have had an opportunistic infection (eg, herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
* Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section 26 on: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation Rules.
* Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
* Currently have any known malignancy or have a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.
* Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
D: Inclusion Criteria:

* Chronic HS for \> 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS
* Localizes to skin folds including any of axillx, breast, abdomen and groin
* active disease
* Negative pregnancy test within 7 days before the first dose of study drug
* Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study

Exclusion Criteria:

* Concurrent active infection including tuberculosis
* Concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic immunosuppressants, systemic retinoids or ant-TNF agents
* Severe comorbidities (diabetes mellitus requiring insulin, Q F of any severity, MI, unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary disease, history of cancer \*thin 5_ years except cutaneous basal cell or squamous cell carcinoma or in situ cervical carcinoma, history of TB or TB exposure, chronic hepatitis B or C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
* Currently enrolled or enrolled within 90 days prior in any trial for treatment of HS
* Known HIV positive
* Contraindication to etanercept as defined in package insert

Answer: D